NX Prenatal
NX Prenatal: A private diagnostics firm innovating non-invasive tests for adverse pregnancy conditions.
Founded
2013NX Prenatal: A private diagnostics firm innovating non-invasive tests for adverse pregnancy conditions.
Founded to revolutionize prenatal care, NX Prenatal is a private molecular diagnostics company focused on developing non-invasive diagnostic assays for adverse pregnancy conditions such as preterm birth. Utilizing its proprietary NeXosome platform, NX Prenatal isolates and enriches exosome and microvesicle particles from bodily fluids to evaluate biomarkers, providing unprecedented insights into maternal and fetal health. The company’s core mission is to enhance prenatal health outcomes through advanced, safe, and convenient maternal blood testing.
NX Prenatal has garnered attention from notable figures in the medical and biotechnology sectors, attracting significant investment to propel its innovative research and development. The company's key achievements include the successful development of diagnostic assays that offer early detection of pregnancy complications, thereby improving clinical decision-making and patient care. Overall, NX Prenatal's impact lies in its potential to transform prenatal diagnostics, ultimately contributing to healthier pregnancies and better neonatal outcomes.
Companies similar to NX Prenatal include NX Pharmagen, KellBenx, Proteogenix and Mirvie.
NX Prenatal was founded in 2013.
NX Prenatal's headquarters is located in Louisville, KY, US.
NX Prenatal's most recent funding round was for $3.1M (USD) in August 2023.
As of Aug 21, 2023, NX Prenatal has disclosed funding of $8.1M (USD). Undisclosed round amounts are excluded.
NX Prenatal has 5 employees as of Feb 5, 2024.
mirvie.com
